康德萊醫械(01501.HK)中期純利增長42.58%至6739.3萬元
格隆匯 8 月 18日丨康德萊醫械(01501.HK)發佈公告,截至2020年6月30日止六個月,實現收入人民幣1.72億元,同比增長27.23%;毛利人民幣1.14億元,同比增長37.18%;公司權益股東應占利潤人民幣6739.3萬元,同比增長42.58%;基本及攤薄每股盈利人民幣0.41元;不派息。
報告期內,集團的收入同比增加約27.23%,該增加主要是由於來自生產及銷售口罩的貢獻所致。就按不同產品分類的收入而言,集團於報告期銷售介入醫療器械產生的收入約為人民幣1.167億元,較2019年同期減少人民幣647萬元。集團於報告期銷售口罩及醫療標準件產生的收入分別約為人民幣4368萬元及人民幣618萬元(2019年同期:無及人民幣749萬元)。2020年初為應對新冠疫情爆發而開展的口罩業務貢獻了報告期25.42%的收入。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.